Stockscreener 앱 받기
2.35
2.08%
-0.05
시장 영업 전:
2.34
-0.01
-0.43%
Neurobo Pharmaceuticals Inc 주식(NRBO)의 최신 뉴스
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024... - Yahoo Finance
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation - Simply Wall St
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency
Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat
Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance
BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com
Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World
Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat
Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World
Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com
BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance
Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize
Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance
Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg
Novo drops to 1-month low after Monlunabant trial data - XM
NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia
NeuroBo shareholders approve significant stock issuance - Investing.com India
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena
NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial - TipRanks
NeuroBo partners for long-acting obesity treatment - Investing.com India
NeuroBo Partners for Monthly Dual-Action Diabetes Drug Development - TipRanks
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - StockTitan
NeuroBo licenses diabetic neuropathy drug to MThera Pharma By Investing.com - Investing.com Nigeria
0.93%
3.55%
자본화:
|
볼륨(24시간):